Women Are Less Frail at 80 But More Frail at 100 — Inflammation Tells the Story

The sex-frailty paradox — the observation that women outlive men yet carry higher frailty burdens — has long puzzled gerontologists. This study from Italian researchers at the University of Milan and IRCCS institutes provides one of the most granular biological explorations of the paradox to date, using a 10-year longitudinal cohort of 452 community-recruited subjects (315 women, 137 men, ages 43–114) stratified into three age bands: ≤80 years, 81–99 years, and ≥100 years (centenarians).

Frailty was quantified using a validated 47-item Frailty Index (FI), which aggregates deficits across physical, cognitive, functional, and symptomatic domains. Results showed a clear age-related rise in FI across the entire cohort (p<0.001). However, the sex comparison within age bands produced a striking pattern: women ≤80 years were significantly less frail than men (FI 0.14 vs. 0.21, p<0.001), women 81–99 years showed no significant difference from men (FI 0.22 vs. 0.24, p=0.14), and centenarian women trended toward greater frailty than centenarian men (FI 0.55 vs. 0.48, p=0.06). This reversal in frailty advantage across age groups is a central empirical contribution of the paper.

Inflammatory biomarkers were measured in plasma using next-generation ELISA (Ella/Simple Plex platform), capturing IFN-γ, IL-10, IL-6, IL-1β, TNF-α, TNFR1, sTREM-1, sTREM-2, and neurofilament light chain (NfL). Men aged ≤80 years showed significantly higher concentrations of IL-10 (p=0.04), IL-6 (p=0.04), TNF-α (p=0.02), and sTREM-1 (p=0.02) compared to women of the same age. In the 81–99 group, men retained significantly higher IL-6 (p=0.04), TNFR1 (p=0.004), and sTREM-1 levels. Among centenarians, NfL — a neurodegeneration marker — was significantly lower in men, suggesting less neuroinflammatory burden in male survivors reaching age 100.

Multiple linear regression confirmed that most biomarkers were independently associated with both age and frailty (log-transformed FI), but the direction and strength of these associations differed by sex. This sex-specific divergence in inflammaging architecture suggests that men and women follow distinct immunological trajectories through aging: men mount a more aggressive and earlier pro-inflammatory response, while women may sustain lower-grade inflammation for longer before it intensifies near the end of life. This could help explain why men die earlier from acute inflammatory-driven diseases (cardiovascular events, stroke) while women accumulate chronic disabling conditions over extended lifespans.

The clinical and scientific implications are substantial. The finding that inflammatory markers such as IL-6, TNFR1, and sTREM-1 are robustly elevated in men across midlife and older adulthood, yet men are less frail, challenges simple cause-and-effect models of inflammaging. It suggests either that women are more sensitive to inflammation-induced functional decline, or that their survival advantage comes partly from a more regulated (though ultimately costly) immune response. The authors call for sex-stratified biomarker reference ranges and sex-specific therapeutic targets in anti-aging interventions, a practical takeaway for clinicians designing longevity protocols.